Key Highlights

  • Oncolytics signed a clinical Supply agreement with Coherus Oncology for a planned study.
  • The study will combine pelareorep with Coherus's PD-1 inhibitor LOQTORZI in squamous cell anal carcinoma.
  • Patients enrolled will have progressed on first-line chemotherapy and checkpoint inhibition.
  • The study is expected to begin in the first quarter of 2027.

Oncolytics Biotech Inc. (NASDAQ:ONCY), a clinical-stage immunotherapy company developing pelareorep, has signed a clinical supply agreement with Coherus Oncology to evaluate pelareorep alongside Coherus's PD-1 inhibitor LOQTORZI in squamous cell anal carcinoma. The company said the study is expected to start in the first quarter of 2027. The arrangement was announced on November 11, 2026. Oncolytic viruses are a class of immunotherapy designed to infect and destroy tumor cells while stimulating an immune response, and they are often tested in combination with approved drugs.

The Supply Agreement

Under the clinical supply agreement, Coherus will provide LOQTORZI, toripalimab-tpzi, to Oncolytics for the planned study. Oncolytics is expected to partner with the institution sponsoring the study, which will be named once the trial begins at a premier U.S. cancer center.

The update does not disclose financial terms such as payments or milestones, so the commercial value of the arrangement cannot be determined from it.

Combining an investigational agent with an approved checkpoint inhibitor is a common development approach, since it allows researchers to test whether the two therapies work better together than alone.

The Patient Population

The study will enroll patients who have progressed on the current first-line standard of care, chemotherapy combined with checkpoint inhibition. The company said there is no approved therapy for second-line patients with this cancer, which defines a clear unmet need.

The design pairs an investigational oncolytic virus immunotherapy with a PD-1 inhibitor already on the market. The company said this supports a focused evaluation in a difficult-to-treat patient group.

Squamous cell anal carcinoma is a rare cancer, and trials in rare cancers often face enrollment challenges. The planned study's location at a major cancer center may help with patient access, though the update does not name the site.

Development Timing

The study is expected to begin in the first quarter of 2027. Because the trial has not started and the institution has not been named, the milestones remain ahead rather than achieved.

The update does not provide data from earlier studies of pelareorep in this indication, so the scientific basis for the combination rests on the design of the planned study.

A supply agreement typically covers the drug that a partner provides, while the sponsor funds the study itself. The update does not describe who will pay for trial costs, which is a key point for assessing the company's exposure.

Risks and Open Questions

Early-stage immunotherapy trials carry the usual risks of limited efficacy, unexpected safety signals and delays in enrollment or site activation. The update does not describe the trial's endpoints or sample size, which will determine how informative it is.

The company's cash position and funding plan are not discussed in the material reviewed, so its ability to run the study on schedule cannot be assessed from it.

Any early results would need to be read against the standard of care and the small size of such studies. The update does not set out the primary endpoints or how success will be measured.

Final Word

Oncolytics has secured a supply arrangement for a combination study in a population with no approved second-line option, with the trial scheduled to begin in early 2027. The update leaves the study design, funding and data milestones open, so progress will be judged on the trial start, enrollment and any early results. The start of enrollment and the first data from the study will be the next milestones to watch.